Neuroticism (Nagel 2018) |
1.09 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MYST1 |
Worry (Nagel 2018) |
1.09 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
MYST1 |
Alzheimer’s Disease (in mother) |
32.81 |
21 |
10 |
22.2 |
1.00 |
1.4e-32 |
APOC1 APOC1P1 APOC4 BIN1 BLOC1S3 CEACAM19 CR1 CTB-179K24.3 FCER1G GEMIN7 KLC3 MYST1 PICALM PMS2L1 PVR PVRL2 SLC24A4 TOMM40 TRAPPC6A VASP ZNF285 |
Alzheimer’s Disease (in father) |
17.00 |
12 |
7 |
15.6 |
0.98 |
2.5e-12 |
ACE APOC1 APOC1P1 APOC4 C17orf87 CEACAM19 GEMIN7 PICALM PMS2L1 PVRL2 TOMM40 ZNF285 |
Crohns Disease (2017) |
0.97 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
BIN1 CASS4 |
Irritable Bowel Disease (IBD) |
0.96 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CASS4 |
HDL Cholesterol |
2.09 |
4 |
0 |
0.0 |
-0.54 |
3.5e-01 |
APOC1 APOC4 PVRL2 TOMM40 |
LDL Cholesterol |
12.73 |
9 |
8 |
17.8 |
0.63 |
2.7e-02 |
APOC1 APOC4 CEACAM19 GEMIN7 KLC3 PVR PVRL2 TOMM40 ZNF285 |
Triglycerides |
3.78 |
5 |
4 |
8.9 |
0.46 |
3.6e-01 |
APOC1 APOC4 MYST1 PVRL2 TOMM40 |
Blood Eosinophil Count |
1.21 |
8 |
6 |
13.3 |
-0.27 |
4.8e-01 |
APOC1 APOC4 C17orf87 CEACAM19 FCER1G INPP5D MYST1 TOMM40 |
Blood Platelet Count |
1.82 |
17 |
6 |
13.3 |
0.00 |
9.9e-01 |
APOC1 APOC4 BLOC1S3 C17orf87 CD2AP CEACAM19 CTB-179K24.3 FCER1G KLC3 PICALM PTK2B PVR PVRL2 STYX TOMM40 VASP ZNF285 |
Blood Red Count |
0.53 |
6 |
1 |
2.2 |
-0.58 |
2.3e-01 |
BLOC1S3 CTB-179K24.3 FCER1G KLC3 MYST1 PVRL2 |
Blood White Count |
1.48 |
11 |
8 |
17.8 |
-0.22 |
4.6e-01 |
APOC1 APOC1P1 APOC4 C17orf87 CR1 FCER1G MS4A2 PTK2B PVR PVRL2 TOMM40 |
Heel T-Score |
0.99 |
4 |
3 |
6.7 |
0.96 |
4.2e-02 |
MS4A2 MYST1 SIX5 VASP |
BMI |
1.41 |
6 |
1 |
2.2 |
-0.75 |
8.4e-02 |
C17orf87 MYST1 PTK2B PVRL2 STYX TOMM40 |
Height |
0.56 |
9 |
5 |
11.1 |
-0.14 |
6.7e-01 |
ACE APOC1 APOC2 APOC4 CD2AP CEACAM19 GEMIN7 MYST1 PICALM |
Waist Hip Ratio (WHR) |
0.66 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
APOC1 FCER1G |
Systolic Blood Pressure |
0.98 |
6 |
2 |
4.4 |
-0.10 |
8.4e-01 |
ACE APOC1 APOC4 BIN1 STYX TOMM40 |
Allergy or Eczema |
1.28 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
FCER1G PVRL2 |
Cardiovascular Disease |
2.38 |
6 |
5 |
11.1 |
0.40 |
4.3e-01 |
ACE APOC4 MYST1 PVRL2 TOMM40 ZNF285 |
Respiratory disease |
1.22 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PVRL2 |
Type 2 Diabetes (T2D) (2018) |
1.68 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
ACE PVRL2 |
Lung FEV1/FVC ratio |
0.69 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
PMS2L1 PTK2B SIX5 |
Lung FVC |
0.85 |
5 |
1 |
2.2 |
0.63 |
2.5e-01 |
APOC1P1 MYST1 PMS2L1 PVRL2 TOMM40 |
Neuroticism |
1.06 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
CTB-179K24.3 MYST1 |
Chronotype (morning person) |
1.16 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ZNF285 |
Hair Pigment |
0.18 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
SLC24A4 TOMM40 |
Hand grip strength (left) |
1.45 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
APOC1P1 MYST1 PVRL2 |
Number of treatments/medications taken |
1.23 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ACE |
Systolic blood pressure, automated reading |
0.72 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
BIN1 STYX |
Medication: Metformin |
1.89 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
APOC1 PVRL2 |
Diabetes (mother) |
1.57 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PVRL2 |
Impedance of leg (right) |
0.49 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MYST1 |
Leg fat-free mass (left) |
0.95 |
3 |
1 |
2.2 |
-0.87 |
1.3e-01 |
APOC4 MYST1 STYX |
Trunk fat percentage |
1.12 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
MYST1 PVRL2 |
Hand grip strength (right) |
1.55 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
APOC1P1 PVRL2 STYX |
Average weekly fortified wine intake |
2.13 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TOMM40 |
Heel bone mineral density (BMD) T-score, automated (left) |
0.99 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
MS4A2 |
High blood pressure |
1.35 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
ACE MYST1 |
Hayfever, allergic rhinitis or eczema |
1.20 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PVRL2 |
Sitting height |
0.36 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PICALM |
Body mass index (BMI) |
1.34 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
C17orf87 MYST1 PVRL2 |
Impedance of leg (left) |
0.49 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MYST1 |
Leg predicted mass (left) |
0.96 |
4 |
1 |
2.2 |
-0.84 |
3.8e-02 |
APOC1 APOC4 MYST1 STYX |
Trunk fat mass |
1.26 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
APOC4 MYST1 PVRL2 |
Waist circumference |
1.47 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
MYST1 PTK2B PVRL2 |
Number of incorrect matches in round |
0.87 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
MYST1 |
Nervous feelings |
1.14 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
MYST1 |
Forced vital capacity (FVC) |
0.82 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
MYST1 PVRL2 |
Heel bone mineral density (BMD) T-score, automated (right) |
0.79 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
MS4A2 |
Financial difficulties in last 2 years |
1.20 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MYST1 |
Diabetes (self-reported) |
1.78 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
APOC1 |
Medication: Simvastatin |
3.50 |
4 |
2 |
4.4 |
0.98 |
1.9e-02 |
CEACAM19 PVR PVRL2 TOMM40 |
Fluid intelligence score |
0.90 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PVRL2 |
Illnesses of siblings |
1.26 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MYST1 |
Weight |
1.35 |
5 |
1 |
2.2 |
-0.84 |
1.8e-02 |
APOC1 APOC4 C17orf87 MYST1 STYX |
Impedance of arm (right) |
0.58 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
BLOC1S3 GEMIN7 MYST1 |
Arm fat percentage (right) |
1.26 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
ACE MYST1 PVRL2 |
Trunk fat-free mass |
0.94 |
4 |
2 |
4.4 |
-0.94 |
5.1e-03 |
APOC1 APOC2 APOC4 MYST1 |
Hip circumference |
1.37 |
3 |
1 |
2.2 |
-0.90 |
9.8e-02 |
APOC4 MYST1 STYX |
Worrier / anxious feelings |
1.19 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MYST1 |
Forced expiratory volume in 1-second (FEV1) |
0.86 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
MYST1 PVRL2 |
Pulse rate |
0.99 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PMS2L1 |
Asthma |
1.00 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PVRL2 |
Medication: Cholesterol lowering |
2.93 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
PVRL2 TOMM40 |
Forced expiratory volume in 1-second (FEV1), Best measure |
0.80 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
MYST1 PVRL2 |
Impedance of arm (left) |
0.63 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MYST1 |
Arm fat mass (right) |
1.44 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
C17orf87 MYST1 PVRL2 |
Trunk predicted mass |
0.93 |
4 |
2 |
4.4 |
-0.94 |
5.1e-03 |
APOC1 APOC2 APOC4 MYST1 |
Standing height |
0.56 |
5 |
2 |
4.4 |
-0.14 |
7.8e-01 |
APOC1 APOC2 APOC4 CD2AP PICALM |
Tense / 'highly strung' |
1.04 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MYST1 |
Peak expiratory flow (PEF) |
0.93 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PTK2B |
Loud music exposure frequency |
1.58 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TOMM40 |
Medication for cholesterol, blood pressure or diabetes |
1.95 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
ACE PMS2L1 TOMM40 |
Birth weight |
1.16 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PVRL2 |
High blood pressure (siblings) |
1.76 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
MYST1 |
Forced vital capacity (FVC), Best measure |
0.80 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
MYST1 PVRL2 |
Body fat percentage |
1.21 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
MYST1 PTK2B PVRL2 |
Leg fat percentage (right) |
1.21 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
MYST1 PTK2B |
Arm fat-free mass (right) |
0.91 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
APOC2 APOC4 MYST1 |
Comparative body size at age 10 |
0.59 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MYST1 |
Qualifications: College or University degree |
0.80 |
2 |
0 |
0.0 |
0.00 |
1.0e+00 |
KLC3 TRAPPC6A |
Eye problems/disorders: None of the above |
1.22 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
CASS4 |
Medication for pain relief, constipation, heartburn |
1.05 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ACE |
Medication: Blood pressure |
1.46 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
ACE PMS2L1 |
Whole body fat mass |
1.34 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
MYST1 PVRL2 |
Leg fat mass (right) |
1.43 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
C17orf87 MYST1 |
Arm predicted mass (right) |
0.88 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
APOC4 MYST1 |
Pulse rate, automated reading |
0.76 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
PMS2L1 |
Alcohol intake frequency. |
0.92 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
MYST1 |
Comparative height size at age 10 |
0.55 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
APOC2 APOC4 CD2AP |
Overall health rating |
1.12 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
MYST1 PVRL2 |
Had major operations |
1.47 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PTK2B |
Knee pain experienced in last month |
1.08 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MYST1 |
Hypertension (Self-reported) |
1.40 |
2 |
2 |
4.4 |
0.00 |
1.0e+00 |
ACE MYST1 |
Whole body fat-free mass |
0.96 |
4 |
2 |
4.4 |
-0.93 |
7.4e-03 |
APOC1 APOC2 APOC4 MYST1 |
Leg fat-free mass (right) |
0.94 |
6 |
2 |
4.4 |
-0.76 |
3.0e-02 |
APOC1 APOC2 APOC4 C17orf87 MYST1 STYX |
Arm fat percentage (left) |
1.22 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
ACE MYST1 PVRL2 |
Long-standing illness, disability or infirmity |
1.03 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PVRL2 |
Diabetes diagnosed by doctor |
2.11 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
ACE APOC1 PVRL2 |
Mouth/teeth dental problems: Mouth ulcers |
1.24 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
FCER1G |
Medication for cholesterol |
1.57 |
3 |
0 |
0.0 |
0.00 |
1.0e+00 |
ACE MYST1 PVRL2 |
Asthma (self-reported) |
1.02 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
PVRL2 |
Illnesses of father: None of the above (group 1) |
1.78 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
TOMM40 |
Forced expiratory volume in 1-second (FEV1), predicted percentage |
1.19 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
MYST1 PVRL2 |
Whole body water mass |
0.94 |
4 |
2 |
4.4 |
-0.93 |
7.9e-03 |
APOC1 APOC2 APOC4 MYST1 |
Leg predicted mass (right) |
0.94 |
6 |
1 |
2.2 |
-0.75 |
3.2e-02 |
APOC1 APOC2 APOC4 C17orf87 MYST1 STYX |
Arm fat mass (left) |
1.38 |
3 |
1 |
2.2 |
0.00 |
1.0e+00 |
C17orf87 MYST1 PVRL2 |
Medication: Blood pressure |
1.17 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
ACE MYST1 |
High cholesterol (Self-reported) |
5.29 |
6 |
4 |
8.9 |
0.93 |
2.1e-03 |
APOC4 CEACAM19 PVR PVRL2 TOMM40 ZNF285 |
Medication: Bendroflumethiazide |
0.88 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MYST1 |
Medication: Atorvastatin |
2.45 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
PVRL2 TOMM40 ZNF285 |
Illnesses of father: High blood pressure |
1.36 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ACE |
Basal metabolic rate |
1.07 |
5 |
2 |
4.4 |
-0.82 |
2.3e-02 |
APOC1 APOC2 APOC4 C17orf87 MYST1 |
Leg fat percentage (left) |
1.25 |
1 |
1 |
2.2 |
0.00 |
1.0e+00 |
MYST1 |
Arm fat-free mass (left) |
1.04 |
4 |
2 |
4.4 |
-0.88 |
5.1e-02 |
APOC2 APOC4 C17orf87 MYST1 |
Diastolic blood pressure, automated reading |
0.86 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
ACE MYST1 |
Commuting to job workplace: Cycle |
0.85 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
ZNF229 |
Vascular/heart problems diagnosed by doctor |
1.41 |
3 |
2 |
4.4 |
0.00 |
1.0e+00 |
ACE MYST1 PTK2B |
Cholesterol lowering medication |
3.59 |
5 |
2 |
4.4 |
0.84 |
7.8e-02 |
APOC4 MYST1 PVRL2 TOMM40 ZNF285 |
Pain experienced in last month |
0.76 |
1 |
0 |
0.0 |
0.00 |
1.0e+00 |
MYST1 |
Impedance of whole body |
0.64 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
BLOC1S3 MYST1 |
Leg fat mass (left) |
1.46 |
2 |
1 |
2.2 |
0.00 |
1.0e+00 |
C17orf87 MYST1 |
Arm predicted mass (left) |
1.07 |
4 |
2 |
4.4 |
-0.91 |
1.1e-02 |
APOC1 APOC2 APOC4 MYST1 |